Skip to main content
Premium Trial:

Request an Annual Quote

Pfizer Closes $25M Investment in Monogram

NEW YORK, May 22 (GenomeWeb News) - Pfizer's $25-million investment in Monogram Biosciences closed today, with the conversion price of the convertible note set at $2.70 per share, said Monogram Biosciences.


As GenomeWeb News reported May 8, Pfizer Pharmaceuticals said it would invest $25 million in Monogram through a 3-percent senior secured convertible note, payable in 2010.


The note, dated May 19, is due May 19, 2010, unless converted earlier. The note will be payable quarterly in cash, or at Monogram's option in its common stock, the company said.


The conversion price is at a 20-percent premium to the average closing price of common stock during the five trading days preceding the note's issue. The note will automatically convert if the closing price is greater than $4.06, or 150 percent of the conversion price, for 20 out of 30 consecutive trading days.


The note is secured by all assets related to Monogram's HIV testing business.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.